Evidence map›Paper›PMID 31455273›Full record

ArticleBMC ophthalmology2019

Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with diabetic macular edema treated with ranibizumab.

Yuxiang Hu, Yi Cheng, Xiaoxuan Xu, Bo Yang, Feng Mei, Qiong Zhou, Li Yan, Jun Wang, Xiaorong Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuxiang HuDepartment of Ophthalmology, the First Affiliated Hospital of Nanchang University, No. 17, Nanchang, 330006, China.
Yi ChengDepartment of Ophthalmology, the First Affiliated Hospital of Nanchang University, No. 17, Nanchang, 330006, China.
Xiaoxuan XuDepartment of Ophthalmology, the First Affiliated Hospital of Nanchang University, No. 17, Nanchang, 330006, China.
Bo YangDepartment of Ophthalmology, Xinjiang People's Hospital, Urumqi, China.
Feng MeiDepartment of Ophthalmology, the First Affiliated Hospital of Nanchang University, No. 17, Nanchang, 330006, China.
Qiong ZhouDepartment of Ophthalmology, the First Affiliated Hospital of Nanchang University, No. 17, Nanchang, 330006, China.
Li YanDepartment of Ophthalmology, the First Affiliated Hospital of Nanchang University, No. 17, Nanchang, 330006, China.
Jun WangSecond Department of Respiratory Disease, Jiangxi Provincial People's Hospital, Nanchang, China.
Xiaorong WuDepartment of Ophthalmology, the First Affiliated Hospital of Nanchang University, No. 17, Nanchang, 330006, China. wxr98021@126.com.ORCID http://orcid.org/0000-0001-8618-6798

Funding

Health Development Planning Commission Science Foundation of Jiangxi Province 20185118Jiangxi Provincial Department of Science and Technology 20141BBG70027Key Foundation of Education Department of Jiangxi Province GJJ160033National Natural Science Foundation of China 81760179, 81360151Natural Science Foundation of Jiangxi Province 20171BAB205046
6 · The paper itself

Abstract

backgroundTo investigate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in patients with diabetic macular edema (DME) treated monthly with ranibizumab.

methodsWe retrospectively analyzed the medical records of all patients who received intravitreal ranibizumab (IVR) treatment for DME at the First Affiliated Hospital of Nanchang University between December 2015 and December 2017. Clinicopathological parameters, including NLR, were evaluated to identify predictors of better outcomes of IVR monotherapy.

resultsNinety-one treatment-naïve eyes treated with IVR for DME were retrospectively analyzed in this study. Baseline best-corrected visual acuity (BCVA), neutrophils, NLR, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio were negatively correlated with the changes in BCVA at 24 weeks compared with the baseline, while baseline central retinal thickness and lymphocytes were positively correlated with the changes in BCVA at 24 weeks compared with the baseline. Multiple linear regression analysis revealed that NLR was independently associated with the mean change of BCVA between baseline and week 24. In addition, patients with NLR < 2.27 showed a better improvement in letter score than those with NLR > 2.27.

conclusionPretreatment NLR is independently associated with the BCVA in DME patients treated with IVR, and higher pretreatment NLR may contribute to inferior BCVA outcomes.

Indexed as

Angiogenesis InhibitorsDiabetic RetinopathyFemaleFluorescein AngiographyHumansIntravitreal InjectionsLeukocyte CountLymphocytesMacular EdemaMaleMiddle AgedNeutrophilsPrognosisRanibizumabRetrospective StudiesTomography, Optical CoherenceAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AVEGFA protein, humanDiabetic retinopathyMacular edemaNeutrophil–lymphocyte ratioPredictorsPrognosis

Identifiers

PMID31455273
PMCPMC6712590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.